UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$21.6B |
| 2 |
Amazon
AMZN
|
+$13.7B |
| 3 |
NVIDIA
NVDA
|
+$3.87B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.89B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.4B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$22.7B |
| 2 |
Equinix
EQIX
|
+$857M |
| 3 |
Digital Realty Trust
DLR
|
+$655M |
| 4 |
NetEase
NTES
|
+$618M |
| 5 |
Bank of New York Mellon
BNY
|
+$609M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.9% |
| 2 | Financials | 13.9% |
| 3 | Consumer Discretionary | 11.31% |
| 4 | Healthcare | 10.7% |
| 5 | Communication Services | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
876
Tanger
SKT
$3.94B
| $30.9M | 0.01% |
1,011,352
+210,152
| +26% | +$6.44M |
2013 Q2
48 quarters
|
|
877
Wintrust Financial
WTFC
$9.51B
| $30.9M | 0.01% |
249,268
+69,838
| +39% | +$8.01M |
2013 Q2
48 quarters
|
|
878
Ryan Specialty Holdings
RYAN
$4.64B
| $30.9M | 0.01% |
454,269
+121,446
| +36% | +$8.38M |
2021 Q4
14 quarters
|
|
879
Zymeworks
ZYME
$1.78B
| $30.9M | 0.01% |
2,459,513
-1,420,432
| -37% | -$16.9M |
2023 Q1
9 quarters
|
|
880
DELISTED
Skechers
SKX
| $30.7M | 0.01% |
487,318
+93,083
| +24% | +$5.35M |
2013 Q2
48 quarters
|
|
881
Saia
SAIA
$8.9B
| $30.7M | 0.01% |
112,229
+26,146
| +30% | +$7.45M |
2013 Q2
48 quarters
|
|
882
AST SpaceMobile
ASTS
$12.6B
| $30.6M | 0.01% |
655,470
+329,849
| +101% | +$9.55M |
2024 Q3
3 quarters
|
|
883
CAVA Group
CAVA
$6.03B
| $30.5M | 0.01% |
362,456
+125,834
| +53% | +$10.7M |
2023 Q4
6 quarters
|
|
884
Hanover Insurance
THG
$7.88B
| $30.5M | 0.01% |
179,592
+50,561
| +39% | +$8.44M |
2013 Q2
48 quarters
|
|
885
BridgeBio Pharma
BBIO
$12.7B
| $30.4M | 0.01% |
704,357
+99,411
| +16% | +$3.62M |
2019 Q2
24 quarters
|
|
886
Middleby
MIDD
$4.8B
| $30.4M | 0.01% |
210,987
+53,838
| +34% | +$7.59M |
2013 Q2
48 quarters
|
|
887
First American
FAF
$6.34B
| $30.3M | 0.01% |
493,488
+79,342
| +19% | +$4.71M |
2013 Q2
48 quarters
|
|
888
Ovintiv
OVV
$18.5B
| $30.2M | 0.01% |
793,071
-343,409
| -30% | -$12.6M |
2013 Q2
48 quarters
|
|
889
DELISTED
Verint Systems
VRNT
| $30.1M | 0.01% |
1,532,080
-643,067
| -30% | -$11.2M |
2013 Q2
48 quarters
|
|
890
Match Group
MTCH
$9.73B
| $30M | 0.01% |
972,186
+266,507
| +38% | +$7.97M |
2017 Q1
33 quarters
|
|
891
Brinker International
EAT
$8.55B
| $30M | 0.01% |
166,379
+46,010
| +38% | +$7.22M |
2013 Q2
48 quarters
|
|
892
DELISTED
Confluent
CFLT
| $29.5M | 0.01% |
1,184,912
-19,217
| -2% | -$433K |
2022 Q2
12 quarters
|
|
893
Suncor Energy
SU
$88.8B
| $29.5M | 0.01% |
788,435
-156,098
| -17% | -$5.65M |
2024 Q2
4 quarters
|
|
894
Cullen/Frost Bankers
CFR
$9.42B
| $29.5M | 0.01% |
229,498
+62,598
| +38% | +$7.65M |
2013 Q2
48 quarters
|
|
895
Ollie's Bargain Outlet
OLLI
$5.53B
| $29.4M | 0.01% |
223,422
+40,010
| +22% | +$4.58M |
2015 Q3
39 quarters
|
|
896
Nextpower Inc. Common Stock
NXT
$12.5B
| $29.2M | 0.01% |
537,173
+99,683
| +23% | +$5M |
2023 Q3
7 quarters
|
|
897
Jazz Pharmaceuticals
JAZZ
$13.6B
| $29.1M | 0.01% |
274,051
+76,877
| +39% | +$8.35M |
2013 Q2
48 quarters
|
|
898
AbCellera Biologics
ABCL
$4.01B
| $29.1M | 0.01% |
8,471,619
-7,199,444
| -46% | -$17.9M |
2024 Q2
4 quarters
|
|
899
Glaukos
GKOS
$9.9B
| $28.9M | 0.01% |
279,393
+49,399
| +21% | +$4.64M |
2018 Q1
29 quarters
|
|
900
Prosperity Bancshares
PB
$8.02B
| $28.8M | 0.01% |
409,757
+63,606
| +18% | +$4.38M |
2013 Q2
48 quarters
|
|
Similar funds
UBS AM's Q2 2025 Portfolio in Review
As of Q2 2025, UBS AM held 2,749 positions worth $494B, up 26% from $391B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
UBS AM deployed $54.3B of net new capital in Q2 2025, opening 106 new positions and adding to 2,036 existing holdings. Its largest new stake was Amrize Ltd: 12,343,881 shares worth $612M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Microsoft, an estimated $22.7B trimmed.
- UBS AM's largest Q2 2025 buy was Amrize Ltd: 12,343,881 shares worth $612M.
- UBS AM added most to Apple in Q2 2025, an estimated $21.6B increase.
- UBS AM's biggest Q2 2025 reduction was Microsoft, cutting an estimated $22.7B.
- UBS AM fully exited Discover Financial Services in Q2 2025, selling an estimated $356M.
- UBS AM's ten largest holdings make up 28% of its $494B portfolio in Q2 2025.
- UBS AM opened 106 new positions and closed 128 in Q2 2025.
- UBS AM's portfolio value rose 26% quarter-over-quarter to $494B.
Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.